Physical Exercise and Neuroinflammation in Major Depressive Disorder.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 20 02 2019
accepted: 03 06 2019
pubmed: 23 6 2019
medline: 3 4 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with varied prognosis, chronic course, and duration of illness with reduced quality of life. One factor that significantly contributes to the relevant disease burden of MDD is the heterogeneous treatment response patients experience with current treatment options. A variety of experimental protocols in humans and animals have highlighted that inflammation and neuroinflammation are relevant biological factors that interact with external stimuli and neurophysiological mechanisms, and can trigger MDD. It is well established that exercise is efficacious in treating mild to moderate depression with response rates comparable to mainstream therapies such as antidepressant medication and cognitive behavioral therapy. Several studies have shown that physical exercise is beneficial for a range of chronic diseases. Indeed, physical exercise can promote molecular changes that swerve a chronic pro-inflammatory state to an anti-inflammatory state in both periphery and central nervous system. The changes caused by physical exercise include an increase in PGC1α gene expression, a transcriptional co-activator involved in reducing the synthesis and releasing of pro-inflammatory cytokines, and an increase in anti-inflammatory cytokines. PGC1α changes the metabolism of kynurenine towards, and, in turn, it reduces glutamatergic neurotoxicity. Moreover, some studies have shown that physical exercise promotes alterations in the circuitry of monoaminergic neurotransmission, at least in some aspects, through the effects on the release of proinflammatory cytokines. This review will highlight the effects of physical exercise as therapy and its relation with the biological mechanisms involved in the pathophysiology of MDD, with particular emphasis in the interactions among physical exercise, hypothalamic-pituitary-adrenal (HPA) axis, neuroinflammation, and with the neurotransmitters underlying the main brain circuits involved in the MDD.

Identifiants

pubmed: 31228000
doi: 10.1007/s12035-019-01670-1
pii: 10.1007/s12035-019-01670-1
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

8323-8335

Références

Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Endocr Rev. 2000 Feb;21(1):55-89
pubmed: 10696570
Rev Neurosci. 2017 Oct 26;28(7):693-703
pubmed: 28422706
Clin Neurophysiol. 2017 Jun;128(6):903-913
pubmed: 28402866
Med Sci Sports Exerc. 2013 May;45(5):851-9
pubmed: 23190594
CNS Drugs. 2009;23(2):91-101
pubmed: 19173370
Mol Psychiatry. 2013 Oct;18(10):1119-24
pubmed: 22925832
Expert Opin Drug Saf. 2015 Aug;14(8):1291-304
pubmed: 26022537
Psychol Med. 2012 Jun;42(6):1131-49
pubmed: 22008447
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Am J Physiol Cell Physiol. 2016 May 15;310(10):C836-40
pubmed: 27030575
Neural Plast. 2017;2017:8305287
pubmed: 28828187
J Affect Disord. 2008 Mar;106(3):249-55
pubmed: 17716746
Nature. 2008 Jul 24;454(7203):463-9
pubmed: 18650917
J Neuroinflammation. 2016 Feb 29;13(1):51
pubmed: 26925576
Stress. 2011 Sep;14(5):537-48
pubmed: 21438787
J Clin Psychiatry. 2005 Aug;66(8):974-81
pubmed: 16086611
Neuro Endocrinol Lett. 2011;32(1):7-24
pubmed: 21407167
J Affect Disord. 2017 Jun;215:152-155
pubmed: 28334675
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Metabolism. 1989 Feb;38(2):141-8
pubmed: 2536458
Psychosom Med. 2000 Sep-Oct;62(5):633-8
pubmed: 11020092
Neurochem Int. 2002 Nov;41(5):357-65
pubmed: 12176079
J Clin Invest. 2007 Nov;117(11):3463-74
pubmed: 17932564
Biol Psychiatry. 2006 Jun 15;59(12):1151-9
pubmed: 16566899
Cell Physiol Biochem. 2018;48(3):1369-1381
pubmed: 30048986
Psychosom Med. 2007 Sep-Oct;69(7):587-96
pubmed: 17846259
Brain Behav Immun. 2015 Jan;43:110-7
pubmed: 25124710
Cell. 2014 Sep 25;159(1):33-45
pubmed: 25259918
Neuropsychopharmacology. 2008 Dec;33(13):3182-9
pubmed: 18368033
Psychoneuroendocrinology. 2014 Dec;50:106-17
pubmed: 25202830
Br J Sports Med. 2017 Apr;51(8):636-639
pubmed: 27856411
J Clin Endocrinol Metab. 1999 Jun;84(6):1944-8
pubmed: 10372691
Free Radic Biol Med. 2008 Jan 15;44(2):142-52
pubmed: 18191750
Brain Behav Immun. 2015 Aug;48:1-7
pubmed: 25816800
Brain Behav Immun. 2011 Jan;25(1):135-46
pubmed: 20851176
JAMA Psychiatry. 2019 Apr 1;76(4):399-408
pubmed: 30673066
Neurosci Lett. 1999 Aug 20;271(2):126-8
pubmed: 10477118
Neuroscience. 2015 Nov 12;308:180-93
pubmed: 26358368
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
FEBS J. 2015 Feb;282(4):647-72
pubmed: 25495651
J Psychiatr Res. 2015 Sep;68:316-28
pubmed: 26028548
Diabetes Metab J. 2017 Jun;41(3):205-212
pubmed: 28537059
Pharmacol Rep. 2013;65(6):1655-62
pubmed: 24553014
Brain Res. 2019 Jun 15;1713:102-108
pubmed: 30171838
J Affect Disord. 2017 Jan 15;208:214-217
pubmed: 27792965
Depress Anxiety. 2017 Dec;34(12):1116-1122
pubmed: 28672073
Psychol Bull. 2014 May;140(3):774-815
pubmed: 24417575
Front Neuroendocrinol. 1992 Jan;13(1):61-94
pubmed: 1468599
J Neurosci. 1995 Mar;15(3 Pt 1):1768-77
pubmed: 7891134
Cochrane Database Syst Rev. 2013 Sep 12;(9):CD004366
pubmed: 24026850
Neural Plast. 2017;2017:7014146
pubmed: 28529805
Neuroimmunomodulation. 2009;16(5):300-17
pubmed: 19571591
J Physiol. 2009 Dec 1;587(Pt 23):5559-68
pubmed: 19752112
JAMA Psychiatry. 2018 Jun 1;75(6):566-576
pubmed: 29800984
Eur Neuropsychopharmacol. 2012 Mar;22(3):183-99
pubmed: 21920711
Biol Psychol. 2018 Mar;133:79-84
pubmed: 29408464
Neuromolecular Med. 2016 Mar;18(1):1-15
pubmed: 26611102
Interface Focus. 2014 Oct 6;4(5):20140040
pubmed: 25285199
PLoS One. 2015 May 04;10(5):e0124859
pubmed: 25938418
PLoS One. 2016 Oct 20;11(10):e0165071
pubmed: 27764188
Brain Res Bull. 2009 Aug 14;79(6):452-7
pubmed: 19463920
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Clin Hypertens. 2017 Jun 2;23:11
pubmed: 28588902
Cardiovasc Res. 2005 Jun 1;66(3):562-73
pubmed: 15914121
Ann Clin Psychiatry. 2010 Feb;22(1):43-55
pubmed: 20196982
JAMA Netw Open. 2018 Oct 5;1(6):e183605
pubmed: 30646252
Psychoneuroendocrinology. 2012 Mar;37(3):307-16
pubmed: 22226321
JAMA Psychiatry. 2018 Sep 1;75(9):911-917
pubmed: 29955781
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16136-41
pubmed: 25331895
Theor Biol Med Model. 2006 Sep 23;3:33
pubmed: 16995950
J Affect Disord. 2011 Nov;134(1-3):20-31
pubmed: 21163534
Front Neurosci. 2018 Jul 26;12:498
pubmed: 30093853
Mol Neurobiol. 2018 Apr;55(4):3112-3130
pubmed: 28466271
Physiol Rev. 2011 Apr;91(2):461-553
pubmed: 21527731
Neurosci Biobehav Rev. 2012 Oct;36(9):1965-84
pubmed: 22771334
Trends Neurosci. 2015 Oct;38(10):637-658
pubmed: 26442697
Sports Med. 2017 Feb;47(2):343-352
pubmed: 27299747
Eur J Neurosci. 2007 Oct;26(7):1862-9
pubmed: 17868373
Neuropsychobiology. 2009;59(4):191-8
pubmed: 19521110
Med Sci Sports Exerc. 1996 Jul;28(7):822-8
pubmed: 8832535
Mol Neurobiol. 2019 Feb;56(2):1096-1108
pubmed: 29873040
J Psychiatr Res. 2015 Dec;71:48-55
pubmed: 26522871
Neuropharmacology. 2002 Nov;43(6):1026-34
pubmed: 12423672
J Neurosci. 2013 May 8;33(19):8270-5
pubmed: 23658167
Cell. 2012 Dec 7;151(6):1319-31
pubmed: 23217713
Medicina (Kaunas). 2016;52(1):19-27
pubmed: 26987496
PLoS One. 2017 Oct 19;12(10):e0186700
pubmed: 29049348
Braz J Psychiatry. 2016 Jul-Sep;38(3):247-54
pubmed: 27611903
PLoS One. 2010 Jul 28;5(7):e11825
pubmed: 20689575
Neurosci Bull. 2016 Jun;32(3):273-85
pubmed: 27142698
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559
pubmed: 28479211
Brain Sci. 2013 Jan 11;3(1):39-53
pubmed: 24961306
Neuropsychopharmacology. 2015 Jan;40(2):463-71
pubmed: 25074636
J Appl Physiol (1985). 2005 Apr;98(4):1154-62
pubmed: 15772055
J Physiol. 2016 Apr 1;594(7):1855-73
pubmed: 26844666
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):455-63
pubmed: 27268275
Front Neurosci. 2019 Mar 26;13:264
pubmed: 30971882
Cell. 2006 Oct 20;127(2):397-408
pubmed: 17055439
Pharmacol Ther. 2015 Mar;147:1-11
pubmed: 25444754
Scand J Psychol. 2010 Aug;51(4):304-8
pubmed: 20042028
Mol Psychiatry. 2013 Jun;18(6):692-9
pubmed: 23089630
Oxid Med Cell Longev. 2015;2015:610813
pubmed: 25834699
Transl Psychiatry. 2015 Aug 04;5:e611
pubmed: 26241349
Nat Rev Endocrinol. 2009 Jul;5(7):374-81
pubmed: 19488073
Int J Mol Sci. 2018 May 29;19(6):
pubmed: 29843470
Depress Anxiety. 2009;26(7):612-21
pubmed: 19382183
J Physiol. 2016 Nov 15;594(22):6799
pubmed: 27870119
JAMA Psychiatry. 2015 Mar;72(3):268-75
pubmed: 25629589
Behav Brain Res. 2006 Mar 15;168(1):47-55
pubmed: 16290283
Neuroscience. 2015 Aug 6;300:141-54
pubmed: 25981208
Psychoneuroendocrinology. 2013 Jul;38(7):1158-69
pubmed: 23218517
J Neuroinflammation. 2019 Apr 17;16(1):90
pubmed: 30995920
Br J Pharmacol. 2012 Sep;167(1):1-12
pubmed: 22486393
Neurosci Lett. 2006 May 1;398(1-2):145-50
pubmed: 16504400
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Nat Rev Neurosci. 2014 May;15(5):300-12
pubmed: 24713688
Psychoneuroendocrinology. 2016 Dec;74:286-294
pubmed: 27697714
Endocrinol Metab Clin North Am. 1994 Sep;23(3):451-66
pubmed: 7805648
Diabetes Res Clin Pract. 2017 Jul;129:73-78
pubmed: 28511141
Neuropsychopharmacology. 2004 Oct;29(10):1765-81
pubmed: 15213704
Trends Pharmacol Sci. 2007 Apr;28(4):152-6
pubmed: 17331593
PLoS One. 2017 Feb 10;12(2):e0170547
pubmed: 28187125
Curr Opin Psychiatry. 2009 Jan;22(1):32-6
pubmed: 19122532
Neuropsychiatr Dis Treat. 2005 Mar;1(1):51-7
pubmed: 18568124
Curr Zool. 2016 Jun;62(3):293-306
pubmed: 29491917
Neuromolecular Med. 2008;10(2):81-98
pubmed: 18300002
Neuroscience. 2012 Jan 27;202:309-17
pubmed: 22155655
CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33
pubmed: 17511618
World Allergy Organ J. 2012 Jan;5(1):9-19
pubmed: 23268465

Auteurs

Zuleide M Ignácio (ZM)

Laboratory of Physiology, Pharmacology and Psychopathology, Federal University of Southern Frontier, Chapecó, SC, 89815-899, Brazil. zuleideignacio@gmail.com.

Renato S da Silva (RS)

Laboratory of Translational Psychiatry, University of Southern Santa Catarina, Criciúma, SC, Brazil.

Marcos E Plissari (ME)

Laboratory of Physiology, Pharmacology and Psychopathology, Federal University of Southern Frontier, Chapecó, SC, 89815-899, Brazil.

João Quevedo (J)

Laboratory of Translational Psychiatry, University of Southern Santa Catarina, Criciúma, SC, Brazil.
Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Neuroscience Graduate Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Gislaine Z Réus (GZ)

Laboratory of Translational Psychiatry, University of Southern Santa Catarina, Criciúma, SC, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH